AIM ImmunoTech Inc. 已签署一项协议,旨在规划其核心候选药物Ampligen用于治疗晚期胰腺癌的一项拟议三期临床试验。此举标志着该公司在推进该免疫疗法针对这一难治癌症的临床开发进程中迈出了关键一步。
AIM ImmunoTech Inc. 已签署一项协议,旨在规划其核心候选药物Ampligen用于治疗晚期胰腺癌的一项拟议三期临床试验。此举标志着该公司在推进该免疫疗法针对这一难治癌症的临床开发进程中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.